RxDoctor Payments Data

Rex Villegas

Optometrist · Pasadena, CANPI 1992746275

Payments from drug & device makers

$30,543in general payments, 2019–2025

Across 564 payments — averaging $54.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$8K
  • Sun Pharmaceutical Industries Inc.$4K
  • Bausch & Lomb Americas Inc.$3K
  • AbbVie$3K
  • Eyevance Pharmaceuticals LLC$2K
  • Alcon$2K
  • plus $9K from 18 others

What the payments were for

  • Consulting fees$2,0507%
  • Speaking & faculty fees$6,10620%
  • Travel & lodging$8913%
  • Food & beverage$21,28470%
  • Education$2121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,543 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$99,620
Medicare patients
583
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine266$219,073
LumiganBimatoprost291$109,889
Cyclosporine226$96,340
XiidraLifitegrast105$89,675
MieboPerfluorohexyloctane/Pf57$46,420
CequaCyclosporine44$30,537
RocklatanNetarsudil Mesylat/Latanoprost76$27,412
RhopressaNetarsudil Mesylate66$23,084
VyzultaLatanoprostene Bunod47$22,718
Alphagan PBrimonidine Tartrate53$20,498
Latanoprost1,527$14,147
Brimonidine Tartrate307$8,055
TyrvayaVarenicline Tartrate11$6,731
Timolol Maleate536$5,587
Travoprost40$5,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$2,718$352,768623 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$2,888$158,814209 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$8,008$50,495142 claims
Sun Pharmaceutical Industries Inc.Cequa$3,731$30,53744 claims
Oyster Point Pharma, Inc.Tyrvaya$1,044$6,73111 claims
AlconSimbrinza$1,808$5,05319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.

Other optometrist in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →